歌礼制药-B公告,小分子GLP-1R激动剂ASC30用于减重维持的超长效皮下储库型制剂在美国Ib期临床研究中,在肥胖受试者中显示出75天的表观半衰期。8名肥胖受试者单次皮下注射ASC30减重维持制剂(100毫克)后,达到ASC30血药峰浓度的时间为给药后17天(中位数)。给药约75天后,ASC30血药浓度降至Cmax值的百分之五十,即表观半衰期为75天。良好耐受性支持每季度给药一次。ASC30是临床进展最快的每季度一次的肠促胰素药物,有望成为长期体重管理的维持疗法。
歌礼制药-B公告,小分子GLP-1R激动剂ASC30用于减重维持的超长效皮下储库型制剂在美国Ib期临床研究中,在肥胖受试者中显示出75天的表观半衰期。8名肥胖受试者单次皮下注射ASC30减重维持制剂(100毫克)后,达到ASC30血药峰浓度的时间为给药后17天(中位数)。给药约75天后,ASC30血药浓度降至Cmax值的百分之五十,即表观半衰期为75天。良好耐受性支持每季度给药一次。ASC30是临床进展最快的每季度一次的肠促胰素药物,有望成为长期体重管理的维持疗法。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.